I
Isatuximab
Availability of ACE Drug Guidance
No
Biologics Drug Information Overview
Yes
Post-marketing information
Patient Alert Card
Physician Educational Material
Subsidy Information and Financing Scheme
Cancer Drug and Clinical Indication listed in the MediShield Life Outpatient Cancer Drug List
Active ingredient: Isatuximab
General information
Subsidy Information and Financing Scheme
[MSHL] Isatuximab Concentrate For Solution For Infusion 100 mg/5 mL and 500 mg/25 mL
Isatuximab in combination with carfilzomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three prior therapies.
[MSHL] Isatuximab Concentrate For Solution For Infusion 100 mg/5 mL and 500 mg/25 mL
Isatuximab in combination with pomalidomide and dexamethasone for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.
Drug Guidance for Subsidy
Not Applicable
Post Marketing Information
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Sarclisa Concentrate For Solution For Infusion 500 mg/25 mL |
|
Sarclisa Concentrate For Solution For Infusion 100 mg/5 mL |
|